Primary antibodies used were from the following sources: rabbit (Rb) anti-Myc (Cell Signaling, 2278), mouse (Ms) anti-Myc (Cell Signaling, 9B11), Rb anti-actin (Sigma, A2066), Ms anti-FLAG (Sigma F1804), Rb anti-14-3-3 (Santa Cruz, sc-629), Ms anti -Spir-1 (Santa Cruz, sc-517039), Ms anti-Spir-1 (Abcam, ab57463), Rb anti-DDX3 (Cell Signaling, 2635), Rb anti-IKKβ (Cell Signaling, 2684), Rb anti-HA (Sigma, H6908), Ms anti-α-tubulin (Millipore, 05–829), Ms anti-GAPDH (Sigma, G8795), Rb anti-IRF3 (Cell Signaling, 4962), Rb anti-IRF3 (Santa Cruz, SC-9082), Ms anti-COPε (Santa Cruz, sc-133194), Rb anti-phospho-IRF3 Ser396 (Cell Signaling, 4947S) and Rb polyclonal anti-C6 [53 (link)]. For dilutions used for the primary antibodies, see S3 Table . Secondary antibodies used (1:10,000 dilution) were IRDye 680RD-conjugated goat anti-rabbit IgG or anti-mouse IgG and IRDye 800CW-conjugated goat anti-rabbit IgG or anti-mouse IgG (LI-COR).
Reagents used in this study were: anti-c-Myc agarose from Santa Cruz Biotechnology, and monoclonal anti-HA-agarose, clone HA-7, ANTI-FLAG M2 affinity gel and Poly-D-lysine hydrobromide (all from Sigma Aldrich). Human IFNα, human TNF-α and mouse IL-1β were from Peprotech, HMW poly(I:C) and puromycin were from InvivoGen, and doxycycline was from Melford.
Reagents used in this study were: anti-c-Myc agarose from Santa Cruz Biotechnology, and monoclonal anti-HA-agarose, clone HA-7, ANTI-FLAG M2 affinity gel and Poly-D-lysine hydrobromide (all from Sigma Aldrich). Human IFNα, human TNF-α and mouse IL-1β were from Peprotech, HMW poly(I:C) and puromycin were from InvivoGen, and doxycycline was from Melford.